Try
Eli Lilly and Co.
LLYUnited States
64 filed reports · 514 financial concepts · 41 earnings calls · 29 media appearances
Filed reports
64 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 290 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 7,625 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 23 | 221 | Sep 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 7,120 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 6 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 327 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 243 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 12, 2026 | 887 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 4, 2026 | 6 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 30, 2025 | 6 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 318 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 212 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 7, 2025 | 1 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 199 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 1, 2025 | 6 | Open |
Financial data
514 concepts · 14,966 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial464 concepts · 9,228 facts · Dec 2010 to Aug 2026
- Sales rebates and discounts69 · Dec 2015 to Jun 2026
- Accumulated other comprehensive income loss net of tax59 · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value59 · Dec 2013 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Nonoperating income expense58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Costs, expenses, and other57 · Dec 2014 to Jun 2026
- Fair value of securities in an unrealized gain position57 · Dec 2015 to Sep 2025
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Restructuring settlement and impairment provisions57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Stockholders equity (US GAAP)57 · Dec 2013 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in deferred income taxes56 · Dec 2014 to Jun 2026
- Net cash provided by used in financing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in investing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Other operating activities cash flow statement56 · Dec 2014 to Jun 2026
- Payments for proceeds from other investing activities56 · Dec 2014 to Jun 2026
- Payments for repurchase of common stock56 · Dec 2014 to Jun 2026
- Payments of dividends56 · Dec 2014 to Jun 2026
- Proceeds from payments for other financing activities56 · Dec 2014 to Jun 2026
- Repayments of long term debt56 · Mar 2014 to Jun 2026
- Share based compensation56 · Dec 2014 to Jun 2026
Product8 concepts · 3,593 facts · Dec 2014 to Jun 2026
- Revenue3,564 · Dec 2014 to Jun 2026
- Other sales revenue net11 · Dec 2014 to Dec 2017
- Loss contingency number of defendants6 · Sep 2018 to Sep 2019
- R&D Expense4 · Jun 2016 to Sep 2017
- Acquired in-process research and development3 · Dec 2014 to Dec 2015
- Product revenue3 · Dec 2014 to Dec 2016
- Nonoperating income expense1 · Dec 2014
- Research and development expense1 · Jun 2016
Segment27 concepts · 1,602 facts · Dec 2014 to Jun 2026
- Revenue1,207 · Dec 2014 to Jun 2026
- Other sales revenue net53 · Dec 2014 to Mar 2018
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest42 · Dec 2014 to Dec 2018
- Severance costs136 · Dec 2014 to Dec 2018
- Asset impairment charges34 · Dec 2014 to Dec 2018
- Research and development expense excluding acquired in process cost28 · Dec 2022 to Jun 2026
- Product revenue15 · Jun 2015 to Mar 2018
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Research and development asset acquired other than through business combination written off14 · Dec 2022 to Jun 2026
- Segment expenditure addition to long lived assets14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Other depreciation and amortization13 · Dec 2014 to Dec 2018
- Interest expense nonoperating12 · Dec 2022 to Jun 2026
- Depreciation depletion and amortization10 · Dec 2022 to Sep 2025
- Income loss from equity method investments10 · Dec 2022 to Sep 2025
- Income tax expense benefit10 · Dec 2022 to Sep 2025
- Investment income interest10 · Dec 2022 to Sep 2025
- Restructuring costs and asset impairment charges10 · Dec 2022 to Sep 2025
- Pretax Income8 · Jun 2015 to Mar 2017
- Goodwill7 · Dec 2015 to Dec 2018
- Payments to acquire equity method investments5 · Dec 2023 to Sep 2025
- Impairment of intangible assets excluding goodwill2 · Dec 2017 to Dec 2018
Geography3 concepts · 315 facts · Dec 2014 to Jun 2026
- Revenue308 · Dec 2014 to Jun 2026
- Severance costs14 · Dec 2017
- Asset impairment charges3 · Dec 2014 to Dec 2017
Guidance12 concepts · 228 facts · Oct 2021 to Aug 2026
- Effective Tax Rate Guidance48 · Oct 2021 to Aug 2026
- Revenue Guidance48 · Oct 2021 to Aug 2026
- EPS (Diluted) Guidance46 · Oct 2021 to Aug 2026
- Gross Margin Guidance26 · Oct 2021 to Nov 2023
- Operating Margin Guidance24 · Oct 2021 to Aug 2025
- EPS (Diluted) Guidance (Adjusted (non-GAAP))10 · Oct 2021 to Feb 2023
- Gross Margin Guidance (Adjusted (non-GAAP))10 · Oct 2021 to Feb 2023
- Operating Margin Guidance (Adjusted (non-GAAP))6 · Oct 2021 to Dec 2022
- Effective Tax Rate Guidance (Adjusted (non-GAAP))4 · Oct 2021 to Dec 2022
- EPS (Diluted) Growth Guidance2 · Feb 2022
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))2 · Feb 2022
- Revenue Growth Guidance (core business)2 · Feb 2023
Segments
5,510 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis69 members · 3,269 facts
- Jardiance131 · Dec 2016 to Jun 2026
- Immunology113 · Dec 2017 to Jun 2026
- Neuroscience113 · Dec 2017 to Jun 2026
- Oncology113 · Dec 2017 to Jun 2026
- Other Oncology113 · Dec 2017 to Jun 2026
- Taltz113 · Dec 2017 to Jun 2026
- Trulicity113 · Dec 2017 to Jun 2026
- Verzenio113 · Dec 2017 to Jun 2026
- Basaglar110 · Dec 2016 to Dec 2024
- Other Product Total107 · Dec 2017 to Dec 2025
- Olumiant105 · Dec 2017 to Dec 2024
- Other Immunology103 · Mar 2018 to Jun 2026
- Cardiometabolic Health99 · Dec 2018 to Jun 2026
- Other Cardiometabolic Health99 · Dec 2018 to Jun 2026
- Erbitux98 · Dec 2016 to Dec 2024
- Cyramza94 · Dec 2017 to Dec 2024
- Emgality94 · Dec 2017 to Dec 2024
- Humalog94 · Dec 2017 to Dec 2024
- Humulin94 · Dec 2017 to Dec 2024
- Other Product94 · Dec 2017 to Dec 2024
- Other Neuroscience91 · Dec 2017 to Dec 2024
- Forteo90 · Dec 2017 to Sep 2024
- Cialis89 · Dec 2017 to Sep 2024
- Alimta87 · Dec 2017 to Dec 2023
- Zyprexa82 · Dec 2017 to Dec 2024
- Trajenta BI70 · Dec 2016 to Sep 2024
- Cymbalta68 · Dec 2017 to Dec 2022
- Mounjaro67 · Dec 2020 to Jun 2026
- COVID19 Antibodies65 · Dec 2019 to Dec 2024
- TYVYT54 · Dec 2019 to Dec 2024
- Zepbound49 · Dec 2021 to Jun 2026
- Collaborationand Other Revenue47 · Dec 2016 to Jun 2026
- Product47 · Dec 2016 to Jun 2026
- Royalty35 · Dec 2016 to Dec 2023
- Baqsimi32 · Dec 2021 to Dec 2024
- Endocrinology28 · Dec 2017 to Dec 2019
- Other Endocrinology28 · Dec 2017 to Dec 2019
- Strattera27 · Dec 2017 to Dec 2019
- Tyvyt18 · Mar 2023 to Sep 2024
- Other Diabetes And Obesity12 · Dec 2021 to Mar 2024
- Product And Service Other12 · Mar 2025 to Jun 2026
- Bamlanivimab7 · Dec 2018 to Dec 2020
- Jardiance7 · Jun 2017 to Dec 2017
- Trajenta bi7 · Jun 2017 to Dec 2017
- Covid19 antibodies6 · Dec 2020 to Dec 2023
- Erbitux Collaborationand Other Revenue3 · Dec 2016 to Dec 2018
- Erbitux Product3 · Dec 2016 to Dec 2018
- Zepbound3 · Dec 2022 to Dec 2023
- Other immunology2 · Dec 2017 to Dec 2018
- Alimta1 · Dec 2017
- Basaglar1 · Dec 2017
- Cialis1 · Dec 2017
- Cymbalta1 · Dec 2017
- Cyramza1 · Dec 2017
- Endocrinology1 · Dec 2017
- Erbitux1 · Dec 2017
- Forteo1 · Dec 2017
- Humalog1 · Dec 2017
- Humulin1 · Dec 2017
- Immunology1 · Dec 2017
- Neuroscience1 · Dec 2017
- Oncology1 · Dec 2017
- Other endocrinology1 · Dec 2017
- Other neuroscience1 · Dec 2017
- Other oncology1 · Dec 2017
- Strattera1 · Dec 2017
- Taltz1 · Dec 2017
- Trulicity1 · Dec 2017
- Zyprexa1 · Dec 2017
Statement business segments11 members · 1,602 facts
- Human Pharmaceutical Products1,252 · Dec 2014 to Dec 2018
- Reportable193 · Dec 2022 to Jun 2026
- Animal Health Products68 · Dec 2014 to Dec 2018
- Animal Health35 · Jun 2015 to Sep 2018
- Human pharmaceutical products27 · Dec 2015 to Dec 2018
- Operating Segments6 · Jun 2015 to Mar 2017
- Total6 · Dec 2014 to Dec 2016
- Operating segments6 · Jun 2015 to Mar 2017
- Animal health products5 · Dec 2015 to Dec 2018
- Reportable segment2 · Dec 2024
- Total segment2 · Dec 2015 to Dec 2016
Product or serviceus-gaap:ProductOrServiceAxis32 members · 324 facts
- Erbitux21 · Jun 2015 to Dec 2024
- Alimta14 · Jun 2015 to Sep 2017
- Cialis14 · Jun 2015 to Sep 2017
- Cymbalta14 · Jun 2015 to Sep 2017
- Cyramza14 · Jun 2015 to Sep 2017
- Endocrinology14 · Jun 2015 to Sep 2017
- Forteo14 · Jun 2015 to Sep 2017
- Humalog14 · Jun 2015 to Sep 2017
- Humulin14 · Jun 2015 to Sep 2017
- Neuroscience14 · Jun 2015 to Sep 2017
- Oncology14 · Jun 2015 to Sep 2017
- Other endocrinology14 · Jun 2015 to Sep 2017
- Other neuroscience14 · Jun 2015 to Sep 2017
- Other oncology14 · Jun 2015 to Sep 2017
- Strattera14 · Jun 2015 to Sep 2017
- Trulicity14 · Jun 2015 to Sep 2017
- Zyprexa14 · Jun 2015 to Sep 2017
- Basaglar13 · Mar 2016 to Sep 2017
- Immunology11 · Jun 2016 to Sep 2017
- Taltz11 · Jun 2016 to Sep 2017
- Erbitux9 · Dec 2014 to Dec 2016
- Other immunology9 · Jun 2016 to Jun 2022
- Jardiance4 · Dec 2014 to Dec 2017
- Lanabecestat4 · Jun 2016 to Sep 2017
- Trajenta BI4 · Dec 2014 to Dec 2017
- Basaglar3 · Dec 2014 to Dec 2016
- Effient3 · Dec 2014 to Dec 2016
- Erbitux API3 · Dec 2014 to Dec 2016
- Tanezumab2 · Mar 2015 to Dec 2015
- Bi Compounds1 · Dec 2014
- Lanabecestat1 · Jun 2016
- Lly Compounds1 · Dec 2014
Statement geographicalsrt:StatementGeographicalAxis9 members · 281 facts
- US48 · Dec 2016 to Jun 2026
- Europe47 · Dec 2016 to Jun 2026
- JP47 · Dec 2016 to Jun 2026
- Rest Of World46 · Dec 2016 to Jun 2026
- Non Us42 · Dec 2017 to Jun 2026
- CN38 · Dec 2018 to Jun 2026
- International11 · Dec 2016 to Mar 2019
- Outside United States1 · Dec 2017
- PR1 · Dec 2017
Statement geographicalus-gaap:StatementGeographicalAxis10 members · 34 facts
- US7 · Dec 2014 to Mar 2018
- Europe6 · Dec 2014 to Mar 2018
- JP6 · Dec 2014 to Mar 2018
- Rest Of World6 · Dec 2014 to Mar 2018
- International2 · Mar 2017 to Mar 2018
- Rest of world2 · Dec 2018 to Dec 2023
- PR2 · Dec 2014 to Dec 2017
- Jp1 · Dec 2023
- Outside United States1 · Dec 2017
- Europe1 · Dec 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary125 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary245 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes11 claims from 1 reports · Dec 2025
- Risk factors32 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1Apr 30, 2026
- FY2025 Q4Feb 4, 2026
- FY2025 Q3Oct 30, 2025
- FY2025 Q2Aug 7, 2025
- FY2025 Q1May 1, 2025
- FY2024 Q4Feb 6, 2025
- FY2024 Q3Oct 30, 2024
- FY2024 Q2Aug 8, 2024
- FY2024 Q1Apr 30, 2024
- FY2023 Q4Feb 6, 2024
- FY2023 Q3Nov 2, 2023
- FY2023 Q2Aug 8, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Feb 2, 2023
- FY2022 Q3Nov 1, 2022
Executive media
29 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews12 · Mar 2020 to Jun 2026
- Other appearances11 · Dec 2020 to Jun 2026
- Podcasts5 · Oct 2024 to Sep 2025
- Conference talks1 · Apr 2026
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.